Fampridine Stada 10 mg prolonged-release tablets EFG
Fampridine Stada is a medication used to improve walking in adults (18 years or older) with multiple sclerosis (MS) who have walking disability. In multiple sclerosis, inflammation destroys the protective covering of the nerves, leading to muscle weakness, muscle stiffness, and difficulty walking.
Fampridine Stada contains the active ingredient fampridine, which belongs to a group of medications called potassium channel blockers. They work by slowing the release of potassium from damaged nerve cells in MS. It is believed that this medication works by allowing signals to pass through the nerve in a more normal way, enabling you to walk better.
Talk to your doctorand do not takefampridine if any of these situations apply to you.
Consult your doctor or pharmacist before starting to take fampridine:
Tell your doctor beforetaking fampridine if any of these situations apply to you.
Do not give fampridine to children or adolescents under 18 years of age.
Before starting treatment and during treatment, your doctor may check that your kidneys are working properly.
Tell your doctor or pharmacistif you are using or have recently used or may need to use any other medication.
Your doctor will be particularly careful if you receive fampridine at the same time as another medication (such as carvedilol, propranolol, and metformin) that may affect the elimination of other medications by the kidneys.
Fampridine should be taken without food, on an empty stomach.
If you are pregnantor plan to become pregnant, consult your doctor beforeusing this medication.
Using fampridine during pregnancy is not recommended.
Your doctor will weigh the benefits of treatment with fampridine for you against the risk to the baby.
Breastfeeding should be discontinuedduring treatment with this medication.
Fampridine may affect your ability to drive and use machines, as it may cause dizziness. Make sure it does not affect you before driving or using machines.
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again. Fampridine can only be obtained with a prescription and under the supervision of doctors experienced in MS.
Your doctor will initially prescribe treatment for 2 to 4 weeks. After this period, the treatment will be re-evaluated.
The recommended dose is onetablet in the morning and onetablet in the evening (12 hours apart). Do not take more than two tablets in a day. There must be a 12-hour intervalbetween each tablet. Do not take the tablets more frequently than every 12 hours.
Swallow the tablet wholewith water. Do not divide, crush, dissolve, suck, or chew the tablet, as this may increase the risk of side effects.
Immediately contact your doctorif you take too many tablets. If you go to the doctor, take the fampridine box with you.
If you experience an overdose, you may notice sweating, small tremors (tremors), dizziness, confusion, memory loss (amnesia), and seizures. You may also notice other effects not mentioned here.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take a tablet, do not take a double dose to make up for the missed doses.
There must always be a 12-hour intervalbetween each tablet.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, fampridine can cause side effects, although not everyone will experience them.
If you have a seizure, stop taking fampridine and inform your doctor immediately.
If you experience one or more of the following allergic symptoms (hypersensitivity): swelling of the face, mouth, lips, throat, or tongue, redness or itching of the skin, chest tightness, and breathing difficulties, stop taking fampridineand see a doctor immediately.
The following side effects are listed by frequency:
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medicines Monitoring System: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the packaging after CAD. The expiration date is the last day of the month indicated.
Store below 25°C. Store in the original packaging to protect it from moisture.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the pharmacy's SIGRE collection point. If you have any questions, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Fampridine Stada
Each prolonged-release tablet contains 10 mg of fampridine
Core of the tablets:
Hydroxypropyl methylcellulose
Microcrystalline cellulose
Anhydrous colloidal silica
Magnesium stearate
Coating:
Hydroxypropyl methylcellulose
Titanium dioxide (E-171)
Macrogol
Coated tablet, approximately 13 x 8 mm, oval, and white to off-white, marked with L10 on one side and smooth on the other side.
It is presented in blister packs (aluminum with desiccant/aluminum) packaged in cardboard boxes containing:
14 x 1 (single-dose blister) prolonged-release tablets
28 x 1 (single-dose blister) prolonged-release tablets
56 x 1 (single-dose blister) prolonged-release tablets
196 x 1 (single-dose blister) prolonged-release tablets
Not all pack sizes may be marketed.
Marketing authorization holder:
Laboratorio STADA, S.L.
C/Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
info@stada.es
Manufacturer:
Laboratorios Liconsa S.A.
Avda. Miralcampo, Nº 7
Polígono Industrial Miralcampo
19200 Azuqueca de Henares (Guadalajara)
Spain
or
STADA Arzneimittel AG
Stadastrasse 2 – 18
61118 Bad Vilbel
Germany
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Wien
Austria
Date of the last revision of this package leaflet:March 2022
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS): http://www.aemps.gob.es/